Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association Between Melanoma Detected During Routine Skin Checks and Mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Association Between Drug Use and Subsequent Diagnosis of Lupus Erythematosus

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Does aluminium in sunscreens cause dermatitis in children with aluminium contact allergy: A repeated open application test study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Family burden of hospital-managed pediatric atopic dermatitis: A nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comparison of Cytokines in Skin Biopsies and Tape Strips from Adults with Atopic Dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Chromium and cobalt release from metallic earrings from the Danish market

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. No immediate effect of regulatory reduction of chromium in leather among adult patients with chromium allergy

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Kristian Reich
  • Kenji Kabashima
  • Ketty Peris
  • Jonathan I Silverberg
  • Lawrence F Eichenfield
  • Thomas Bieber
  • Aleksandra Kaszuba
  • Jill Kolodsick
  • Fan E Yang
  • Margaret Gamalo
  • Dennis R Brinker
  • Amy M DeLozier
  • Jonathan M Janes
  • Fabio P Nunes
  • Jacob P Thyssen
  • Eric L Simpson
View graph of relations

Importance: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy studies.

Objective: To assess the efficacy and safety of 4 mg and 2 mg of baricitinib in combination with background topical corticosteroid (TCS) therapy in adults with moderate to severe AD who previously had an inadequate response to TCS therapy.

Design, Setting, and Participants: This double-blind, placebo-controlled, phase 3 randomized clinical trial, BREEZE-AD7 (Study of Baricitinib [LY3009104] in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis) was conducted from November 16, 2018, to August 22, 2019, at 68 centers across 10 countries in Asia, Australia, Europe, and South America. Patients 18 years or older with moderate to severe AD and an inadequate response to TCSs were included. After completing the study, patients were followed up for up to 4 weeks or enrolled in a long-term extension study.

Interventions: Patients were randomly assigned (1:1:1) to receive 2 mg of baricitinib once daily (n = 109), 4 mg of baricitinib once daily (n = 111), or placebo (n = 109) for 16 weeks. The use of low-to-moderate potency TCSs was allowed.

Main Outcomes and Measures: The primary end point was the proportion of patients achieving a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0 (clear) or 1 (almost clear), with a 2-point or greater improvement from baseline at week 16.

Results: Among 329 patients (mean [SD] age, 33.8 [12.4] years; 216 [66%] male), at week 16, a vIGA-AD score of 0 (clear) or 1 (almost clear) was achieved by 34 patients (31%) receiving 4 mg of baricitinib and 26 (24%) receiving 2 mg of baricitinib compared with 16 (15%) receiving placebo (odds ratio vs placebo, 2.8 [95% CI, 1.4-5.6]; P = .004 for the 4-mg group; 1.9 [95% CI, 0.9-3.9]; P = .08 for the 2-mg group). Treatment-emergent adverse events were reported in 64 of 111 patients (58%) in the 4-mg group, 61 of 109 patients (56%) in the 2-mg group, and 41 of 108 patients (38%) in the placebo group. Serious adverse events were reported in 4 patients (4%) in the 4-mg group, 2 (2%) in the 2-mg group, and 4 (4%) in the placebo group. The most common adverse events were nasopharyngitis, upper respiratory tract infections, and folliculitis.

Conclusions and Relevance: A dose of 4 mg of baricitinib in combination with background TCS therapy significantly improved the signs and symptoms of moderate to severe AD, with a safety profile consistent with previous studies of baricitinib in AD.

Trial Registration: ClinicalTrials.gov Identifier: NCT03733301.

Original languageEnglish
JournalJAMA Dermatology
Volume156
Issue number12
Pages (from-to)1333-1343
Number of pages11
ISSN2168-6068
DOIs
Publication statusPublished - 1 Dec 2020

ID: 61444121